In this episode, host Shikha Jain, MD, speaks with Jonathan D. Licht, MD, about becoming and training qualified leaders in the field, challenges facing health care leaders and more.

•    Welcome to another exciting episode of Oncology Overdrive :58
•    About Licht 1:16
•    The interview 3:17
•    Can you tell us about your journey into hematology-oncology and how you ended up where you are today? 3:58
•    How have you found the time and ability to balance and succeed in the research, clinical, translational and leadership parts of your work? 9:05
•    What do you suggest to people who are currently trying to get into leadership positions in their early-to-mid career? 12:52
•    Do you agree with the sentiment that there are some leaders in the field who are put into positions prematurely or are ineffective? As a leader, how do you address the need for further training of future leaders? 18:39
•    What are some of the leadership challenges you have seen in the last several years, and how have you managed to navigate them? 23:20
•    How did you use your leadership skills to navigate the first few years of the pandemic, and how are you continuing to navigate delivery of care post-pandemic? 29:23
•    Tell me about the process of achieving NCI designation and what it means for your institution. 36:25
•    How have you had to navigate state health care legislation and policies challenging reproductive health care? 42:16
•    If someone could only listen to the last minute of this episode, what would you want them to take away? 46:13
•    How to contact Licht 46:56
•    Thanks for listening 48:16

Jonathan D. Licht, MD, is the director of the University of Florida Health Cancer Center.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Licht can be reached on X, formerly known as Twitter, @jdlicht or via email jdlicht@ufl.edu.

Disclosures: Jain reports no relevant financial disclosures. Licht reports consultancy for AstraZeneca and research funding for Epizyme.